Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts

Prostate specific membrane antigen (PSMA) represents a validated target for prostate cancer therapeutics. The phase III VISION study with (177)lutetium ((177)Lu)-PSMA-617 represented a pivotal step forward and the FDA has now approved this agent in advanced metastatic castrate-resistant prostate can...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartor, Oliver, Baghian, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763319/
https://www.ncbi.nlm.nih.gov/pubmed/36561718
http://dx.doi.org/10.3389/fmed.2022.1060922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763319/
https://www.ncbi.nlm.nih.gov/pubmed/36561718
http://dx.doi.org/10.3389/fmed.2022.1060922

Ejemplares similares